Corrigendum: Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Frontiers in Pharmacology, (2019), 10,(1370), 10.3389/fphar.2019.01370);Improvement of sepsis prognosis by ulinastatin: A systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology

Volumn 10, Issue , 2019, Pages

  Wang, Huifang ^a   Liu, Bin ^a   Tang, Ying ^a   Chang, Ping ^a   Yao, Lishuai ^a   Huang, Bo ^a   Lodato, Robert F ^b   Liu, Zhanguo ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Immune system; Inflammatory cytokine; Mortality; Sepsis; Ulinastatin; inflammatory cytokine; immune system; ulinastatin; sepsis; mortality

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; ULINASTATIN;

AGE DISTRIBUTION; ALL CAUSE MORTALITY; APACHE; CLINICAL OUTCOME; CONFIDENCE INTERVAL; DATA BASE; DATA EXTRACTION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; MULTIPLE ORGAN FAILURE; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PUBLICATION BIAS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

EID: 85076699201     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2019.01697     Document Type: Erratum

References (61)

1. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M. R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29 (7), 1303-1310. doi: 10.1097/00003246-200107000-00002
2. Armstrong, B. A., Betzold, R. D., and May, A. K. (2017). Sepsis and septic shock strategies. Surg. Clin. North Am. 97 (6), 1339-1379. doi: 10.1016/j.suc.2017.07.003
3. Atal, S. S., and Atal, S. (2016). Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndrome. J. Basic Clin. Physiol. Pharmacol. 27 (2), 91-99. doi: 10.1515/jbcpp-2015-0003
4. Chang, P., Liu, J., Yu, Y., Cui, S. Y., Guo, Z. H., and Chen, G. M. (2017a). Alphalipoic acid suppresses extracellular histone-induced release of the infammatory mediator tumor necrosis factor-alpha by macrophages. Cell Physiol. Biochem. 42 (6), 2559-2568. doi: 10.1159/000480217
5. Chang, P., Mo, B., Cauvi, D. M., Yu, Y., Guo, Z., and Zhou, J. (2017b). Grape seed proanthocyanidin extract protects lymphocytes against histone-induced apoptosis. PeerJ 5, e3108. doi: 10.7717/peerj.3108
6. Chen, W., Peng, S., and Chen, Y. (2015). Comparative observation of curative effects by ulinastatin and conventional method in the treatment of severe sepsis. Chinese J. Modern Drug App. 9 (7), 1-2, 3. doi: 10.14164/j.cnki. cn11-5581/r.2015.07.001
7. Choudhuri, A. H., Tyagi, R., Tyagi, R., Agarwal, D., and Uppal, R. (2015). Early use of ulinastatin reduces Multiorgan Dysfunction (MODS) in septic shock following anastomotic failure. Clin. Therapeutics 37 (8), e112.
8. Chousterman, B. G., Swirski, F. K., and Weber, G. F. (2017). Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 39 (5), 517-528. doi: 10.1007/s00281-017-0639-8
9. Dai, Q. X., and Wang, C. H. (2016). Effects of urinary trypsin inhibitor on serum levels of TNF-a, IL-8 and IL-10 in patients with severe sepsis. Chinese J. Biochem. Pharmaceutics 36 (3), 146-148. doi: 10.3969/j.issn.1005-1678.2016.03.48
10. Fang, Q., and Chen, P. (2005). A Study on clinical efficacy of ulinastatin in severe sepsis patients and its mechanism of action. Chinese J. Of Infect. And Chemother. 5 (1), 13-16. doi: 10.3321/j.issn:1009-7708.2005.01.003
11. Fang, Q., and Zhao, X. (2017). Clinical effect of combined ulinastatin and continuous renal replacement therapy on management of severe sepsis with acute kidney injury. Tropical J. Pharmaceutical Res. 16 (4), 925-930. doi: 10.4314/tjpr.v16i4.26
12. Fang, M., Zhong, W.-H., Song, W.-L., Deng, Y.-Y., Yang, D.-M., and Xiong, B. (2018). Ulinastatin ameliorates pulmonary capillary endothelial permeability induced by sepsis through protection of tight junctions via inhibition of TNF-alpha and related pathways. Front. Pharmacol. 9, 823. doi: 10.3389/ fphar.2018.00823
13. Feng, Z., Shi, Q., Fan, Y., Wang, Q., and Yin, W. (2016). Ulinastatin and/or thymosin alpha1 for severe sepsis: a systematic review and meta-analysis. J. Trauma Acute Care Surg. 80 (2), 335-340. doi: 10.1097/ta.0000000000000909
14. Girardot, T., Rimmele, T., Venet, F., and Monneret, G. (2017). Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis 22 (2), 295-305. doi: 10.1007/s10495-016-1325-3
15. Han, D., Shang, W., Wang, G., Sun, L., Zhang, Y., and Wen, H. (2015). Ulinastatin- and thymosin alpha1-based immunomodulatory strategy for sepsis: a meta-analysis. Int. Immunopharmacol. 29 (2), 377-382. doi: 10.1016/j. intimp.2015.10.026
16. Harjai, M., Bogra, J., Kohli, M., and Pant, A. B. (2013). Is suppression of apoptosis a new therapeutic target in sepsis?. Anaesth. Intensive Care 41 (2), 175-183. doi: 10.1177/0310057X1304100207
17. Hotchkiss, R. S., and Crouser, E. (2015). Imaging apoptosis in sepsis-A technology we would die for!. Crit. Care Med. 43 (11), 2506-2508. doi: 10.1097/ ccm.0000000000001289
18. Hotchkiss, R. S., and Nicholson, D. W. (2006). Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6 (11), 813-822. doi: 10.1038/nri1943
19. Hotchkiss, R. S., Monneret, G., and Payen, D. (2013). Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 13 (12), 862-874. doi: 10.1038/nri3552
20. Hui, L., Shen, F., Chang, H., Li, X., Gao, G., and Ma, J. (2014). Effects of ulinastatin on cerebral oxygen metabolism and CRP levels in patients with severe traumatic brain injury. Exp. Therapeutic Med. 7 (6), 1683-1686. doi: 10.3892/ etm.2014.1666
21. Inoue, K.-I., and Takano, H. (2010). Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin. Investig. Drugs 19 (4), 513-520. doi: 10.1517/13543781003649533
22. Itaba, S., Nakamura, K., Aso, A., Tokunaga, S., Akiho, H., and Ihara, E. (2013). Prospective, randomized, double-blind, placebo-controlled trial of ulinastatin for prevention of hyperenzymemia after double balloon endoscopy via the antegrade approach. Dig. Endosc. 25 (4), 421-427. doi: 10.1111/den.12014
23. Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., and Gavaghan, D. J. (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin. Trials 17 (1), 1-12. doi: 10.1016/0197-2456(95)00134-4
24. Jiang, L. Y., Hong,Y. L., and Xing, C. J. (2006). The effect of Ulinastatin on the delivery of cytokines in patients with septic shock. Chinese J. Of Emergency Med. 15 (1671-0282), 1136-1138. doi: 10.3760/j.issn:1671-0282.2006.12.020
25. Jiang, W., Yu, X., Sun, T., Chai, Y., Chang, P., and Chen, Z. (2018). ADJunctive Ulinastatin in Sepsis Treatment in China (ADJUST study): study protocol for a randomized controlled trial. Trials 19 (1), 133. doi: 10.1186/s13063-018-2513-y
26. Karnad, D. R., Bhadade, R., Verma, P. K., Moulick, N. D., Daga, M. K., and Chafekar, N. D. (2014). Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 40 (6), 830-838. doi: 10.1007/s00134-014-3278-8
27. Li, G., Li, T., Li, Y., Cai, S., Zhang, Z., and Zeng, Z. (2014). Ulinastatin inhibits oxidant-induced endothelial hyperpermeability and apoptotic signaling. Int. J. Clin. Exp. Pathol. 7 (11), 7342-7350.
28. Li, C., Bo, L., Liu, Q., and Jin, F. (2015). Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int. J. Infect. Dis. 33, 90-96. doi: 10.1016/j.ijid.2014.12.032
29. Li, C., Ma, D., Chen, M., Zhang, L., Zhang, L., and Zhang, J. (2016). Ulinastatin attenuates LPS-induced human endothelial cells oxidative damage through suppressing JNK/c-Jun signaling pathway. Biochem. Biophys. Res. Commun. 474 (3), 572-578. doi: 10.1016/j.bbrc.2016.04.104
30. Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., and Ioannidis, J. P. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700. doi: 10.1136/bmj.b2700
31. Linder, A., and Russell, J. A. (2014). An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med. 40 (8), 1164-1167. doi: 10.1007/s00134-014-3366-9
32. Liu, Z.-G., Zhang, J., He, Y., Chang, P., Gu, D.-S., and Luo, Y.-W. (2011). Impact of transfusion of apoptotic and necrotic thymocytes on the survival of mice with sepsis. J. Of Southern Med. Univ. 31 (6), 960-964.
33. Liu, Z. G., Ni, S. Y., Chen, G. M., Cai, J., Guo, Z. H., and Chang, P. (2013). Histones-mediated lymphocyte apoptosis during sepsis is dependent on p38 phosphorylation and mitochondrial permeability transition. PLoS One 8 (10), e77131. doi: 10.1371/journal.pone.0077131
34. Liu, D., Yu, Z., Yin, J., Chen, Y., Zhang, H., and Fan, X. (2017). Effect of ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian patients. J. Crit. Care 39, 285-287. doi: 10.1016/j. jcrc.2017.02.005
35. Martin, G. S., Mannino, D. M., Eaton, S., and Moss, M. (2003). The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348 (16), 1546-1554. doi: 10.1056/NEJMoa022139
36. Minasyan, H. (2017). Sepsis and septic shock: Pathogenesis and treatment perspectives. J. Crit. Care 40, 229-242. doi: 10.1016/j.jcrc.2017.04.015
37. Ni, H. Y., Fang, Q., and Zhang., Y. S. (2008). Effects of ulinastatin on Inflammatory response and curative effect in severe sepsis patients. Chinese J. Of Crit. Care Med. 28 (4), 342-344. doi: 10.3969/j.issn.1002-1949.2008.04.017
38. Patera, A. C., Drewry, A. M., Chang, K., Beiter, E. R., Osborne, D., and Hotchkiss, R. S. (2016). Frontline Science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J. Leukoc. Biol. 100 (6), 1239-1254. doi: 10.1189/jlb.4HI0616-255R
39. Pavan Kumar Rao, N., Sv, S., and Nayak, K. S. (2017). Use of ulinastatin in renal failure patients developing sepsis. Indian J. Nephrol. 27, S68-S69.
40. Rajaee, A., Barnett, R., and Cheadle, W. G. (2018). Pathogen- and danger-associated molecular patterns and the cytokine response in sepsis. Surg. Infect. (Larchmt) 19 (2), 107-116. doi: 10.1089/sur.2017.264
41. Servillo, G., Vargas, M., Pastore, A., Procino, A., Iannuzzi, M., and Capuano, A. (2013). Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: preliminary data. Biomed. Res. Int. 2013, 108951. doi: 10.1155/2013/108951
42. Shao, Y. M., Zhang, L. Q., Deng, L. H., and Yao, H. G. (2005). [Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 17 (4), 228-230.
43. Shu, H., Liu, K., He, Q., Zhong, F., Yang, L., and Li, Q. (2014). Ulinastatin, a protease inhibitor, may inhibit allogeneic blood transfusion-associated pro-inflammatory cytokines and systemic inflammatory response syndrome and improve postoperative recovery. Blood Transfus. 12 Suppl 1, s109-s118. doi: 10.2450/2013.0224-12
44. Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., and Bauer, M. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama 315 (8), 801-810. doi: 10.1001/jama.2016.0287
45. Song, J. E., Kang, W. S., Kim, D. K., Yoon, T. G., Kim, T. Y., and Bang, Y. S. (2011). The effect of ulinastatin on postoperative blood loss in patients undergoing open heart surgery with cardiopulmonary bypass. J. Int. Med. Res. 39 (4), 1201-1210. doi: 10.1177/147323001103900408
46. Stoller, J., Halpin, L., Weis, M., Aplin, B., Qu, W., and Georgescu, C. (2016). Epidemiology of severe sepsis: 2008-2012. J. Crit. Care 31 (1), 58-62. doi: 10.1016/j.jcrc.2015.09.034
47. Sun, R., Zhang, Y., Lv, Q., Liu, B., Jin, M., and Zhang, W. (2011). Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J. Biol. Chem. 286 (18), 15918-15928. doi: 10.1074/jbc.M110.178798
48. Sung, W. M., Sung, W. L., Yun, S. H., Dae, W. P., Ik, J. J., and Young, H. Y. (2009). The effects of urinary trypsin inhibitor on the outcomes of severe sepsis and septic shock patients. Korean Emergency Medical J. 20, 80-85.
49. Tang, J. (2013). The clinical effect analysis of treating septicopyemia patients with ulinastatin. Guide China Med. (15), 439-440. doi: 10.3969/j. issn.1671-8194.2013.15.333
50. Uchida, M., Abe, T., Ono, K., and Tamiya, N. (2018). Ulinastatin did not reduce mortality in elderly multiple organ failure patients: a retrospective observational study in a single center ICU. Acute Med. Surg. 5 (1), 90-97. doi: 10.1002/ams2.304
51. Wang, Y., Li, X., and Kexi, L. (2007). Influence of Ulinastatin on cytokines of patients with sepsis. Modern Med. J. Of China 9 (11), 23-25. doi: 10.3969/j. issn.1672-9463.2007.11.008
52. Wang, F. Y., Fang, B., Qiang, X. H., Yu, T. O., Zhong, J. R., Cao, J., et al. (2016). The efficacy and immunomodulatory effects of ulinastatin and thymosin alpha1 for sepsis: a systematic review and meta-analysis. Biomed. Res. Int. 2016, 9508493. doi: 10.1155/2016/9508493
53. Wiedow, O., and Meyer-Hoffert, U. (2005). Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J. Intern. Med. 257 (4), 319-328. doi: 10.1111/j.1365-2796.2005.01476.x
54. Wong, W. W. (1998). ICE family proteases in inflammation and apoptosis. Agents Actions Suppl 49, 5-13. doi: 10.1007/978-3-0348-8857-8_2
55. Wu, J., Zhou, L., Liu, J., Ma, G., Kou, Q., and He, Z. (2013a). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care 17 (1), R8. doi: 10.1186/cc11932
56. Wu, T. J., Zhang, L. N., and Kang, C. C. (2013b). The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 25 (4), 219-223. doi: 10.3760/cma.j.i ssn.2095-4352.2013.04.010
57. Wu, Y., Cui, Z. B., Kang, H. S., Zhao,Y. Y. and Liu, S. H. (2016). Effect of ulinastatin on the serum levels of tumor necrosis factor α, interleukin 10,troponin I and C-reactive protein. J. Bengbu Med. College 41 (12), 1635-1638. doi: 10.13898/j. cnki.issn.1000-2200.2016.12.031
58. Xu, Q., Yan, Q., and Chen, S. (2018). Ulinastatin is effective in reducing mortality for critically ill patients with sepsis: a causal mediation analysis. Sci. Rep. 8 (1), 14360. doi: 10.1038/s41598-018-32533-9
59. Yang, H., Mao, Y., Lu, X., Sang, X., Du, S., and Zhao, H. (2011). The effects of urinary trypsin inhibitor on liver function and inflammatory factors in patients undergoing hepatectomy: a prospective, randomized, controlled clinical study. Am. J. Surg. 202 (2), 151-157. doi: 10.1016/j. amjsurg.2010.07.044
60. Zhang, Y., Zhou, Y., Lou, J., Li, J., Bo, L., and Zhu, K. (2010). PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit. Care 14 (6), R220. doi: 10.1186/cc9354
61. Zhang, H., Tan, C., Wang, X., Kang, D., Chen, Y., and Xiong, J. (2016). Preventive effects of ulinastatin on complications related to pancreaticoduodenectomy: a Consort-prospective, randomized, double-blind, placebo-controlled trial. Med. (Baltimore) 95 (24), e3731. doi: 10.1097/md.0000000000003731